Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce W Kirkham et al. · The Lancet · 2015

Cited by 858 works. doi:10.1016/s0140-6736(15)61134-5

Authors

References